Amanta Healthcare Evaluation Sees Shift Amidst Mixed Financial Signals

Quality Parameters Reflect Mixed Financial Health

Amanta Healthcare’s five-year sales growth rate stands at a negative 2.00% compound annual growth rate (CAGR), signalling a contraction in top-line revenue over the medium term. This contrasts with its earnings before interest and tax (EBIT) growth, which shows a positive 9.30% over the same period, suggesting some operational improvements despite sales pressures.

The company’s ability to cover interest expenses is modest, with an average EBIT to interest ratio of 1.30 times, indicating limited cushion against interest obligations. Meanwhile, leverage metrics reveal a Debt to EBITDA ratio averaging 3.27 times and a Net Debt to Equity ratio of 2.51, pointing to a relatively high debt burden that could constrain financial flexibility.

Operational efficiency, measured by sales to capital employed, is at 0.80 times on average, reflecting moderate utilisation of capital resources. The average return on capital employed (ROCE) is 13.97%, which is a respectable figure within the pharmaceuticals sector, while the return on equity (ROE) averages 8.18%, indicating moderate returns to shareholders.

Taxation levels are consistent, with a tax ratio of 28.62%, and the company maintains zero pledged shares, which may be viewed positively from a governance perspective. Institutional holding is relatively low at 12.34%, suggesting limited institutional investor interest compared to some peers.

Valuation and Financial Trend Insights

Amanta Healthcare’s valuation appears attractive when viewed through the lens of enterprise value to capital employed, which is approximately 1.6 times. This suggests that the market values the company at a moderate premium relative to the capital it employs in its operations.

Profitability trends over the past year show a significant rise in profits by 189%, despite the stock price remaining flat with a 0.00% return. This divergence between earnings growth and share price performance may indicate market scepticism or external factors influencing investor sentiment.

However, the company’s long-term sales contraction and elevated debt levels temper the positive signals from profit growth and valuation metrics. The flat results reported in September 2025 further underscore the challenges in sustaining momentum amid a competitive pharmaceuticals and biotechnology sector.

Technical and Market Performance Overview

From a technical perspective, Amanta Healthcare’s stock price closed at ₹102.00, down 1.92% on the day, with intraday trading ranging between ₹95.05 and ₹103.15. The 52-week high stands at ₹154.85, while the 52-week low is ₹95.05, indicating a wide trading range and some volatility over the past year.

Short-term returns have been negative, with a one-week decline of 0.83% and a one-month drop of 16.46%, contrasting with the broader Sensex index, which recorded gains of 0.20% and a marginal decline of 0.46% over the same periods respectively. Year-to-date and longer-term returns for Amanta Healthcare are not available, but the Sensex has posted gains of 8.22% YTD and 4.80% over one year, highlighting relative underperformance by the stock.

Sector Comparison and Peer Positioning

Within the Pharmaceuticals & Biotechnology sector, Amanta Healthcare’s quality metrics place it below average compared to peers such as Shukra Pharma and Venus Remedies, which maintain average quality assessments. Other companies like Fermenta Biotec and Bharat Parenteral also share a below-average standing, indicating a competitive environment with varied financial health among players.

The company’s institutional holding at 12.34% is lower than some peers, which may reflect cautious investor positioning given the company’s financial profile and recent performance trends.

Implications for Investors and Market Outlook

The recent revision in Amanta Healthcare’s evaluation metrics reflects a complex interplay of factors. The company’s subdued sales growth over five years and elevated debt ratios suggest caution, particularly regarding its capacity to sustain growth and service liabilities effectively.

Conversely, the positive EBIT growth and attractive valuation multiples provide some counterbalance, indicating operational improvements and potential value for investors willing to navigate the risks. The significant profit increase over the past year, despite stagnant share price performance, may warrant closer scrutiny to understand underlying drivers and sustainability.

Technical indicators and recent price movements suggest a cautious market stance, with the stock underperforming the broader Sensex index in the short term. Investors may wish to consider these factors alongside sector dynamics and peer comparisons when assessing Amanta Healthcare’s prospects.

Overall, the shift in market assessment underscores the importance of a comprehensive analysis encompassing quality, valuation, financial trends, and technical factors to form a balanced view of the company’s investment potential.

Summary of Key Financial Metrics for Amanta Healthcare

• Five-year sales growth: -2.00% CAGR


• Five-year EBIT growth: 9.30%


• Average EBIT to interest coverage: 1.30 times


• Debt to EBITDA ratio: 3.27 times


• Net Debt to Equity ratio: 2.51


• Sales to capital employed: 0.80 times


• Average ROCE: 13.97%


• Average ROE: 8.18%


• Tax ratio: 28.62%


• Institutional holding: 12.34%


• Current stock price: ₹102.00


• 52-week range: ₹95.05 - ₹154.85

Investors should weigh these metrics carefully in the context of sector trends and broader market conditions to determine the suitability of Amanta Healthcare within their portfolios.

Only Rs. 14,999 - Get MojoOne + Stock of the Week for 1 Year PLUS 18 Months FREE! Start Saving Now →